Resource use and economic burden of respiratory syncytial virus among older adults in real-world clinical practice across five European countries
Open Access
- 19 March 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1773556
Abstract
Introduction: The impact of respiratory syncytial virus (RSV) is increasingly being recognized in older adults, however economic burden data is sparse. This study describes the burden of RSV and associated direct and indirect costs in adults aged 60 + years in real-world clinical practice across five European countries. Methods: Data were drawn from the Adelphi RSV Disease Specific Program (DSP™), a cross-sectional survey of physicians and patients in France, Germany, Italy, Spain, and the United Kingdom conducted December 2023–June 2024. Patients aged 60 + with a confirmed RSV diagnosis were included. Physicians provided data on resource use and supportive care needs, and patients on paid and unpaid productivity loss. Country-specific unit costs were used to calculate direct and indirect costs. Patients were stratified by symptom duration from onset (acute- [A-]RSV: n = 682) provided data on 1,581 patients with RSV (15.0% A-RSV, 12.4% O-RSV, 37.2% P-RSV, and 35.4% H-RSV). For their current RSV infection, patients had a mean of 4.3 visits to any healthcare provider (A-RSV: 3.1–H-RSV: 4.6). H-RSV patients received nearly four times as many tests as A-RSV patients, with 54.8% receiving drugs (versus n = 24), with 18.0% of the 373 patients who responded reporting unpaid productivity loss. Mean direct costs per patient ranged from €320–€6,900 for A-RSV and H-RSV respectively, with hospitalization driving costs in H-RSV. Drug costs trended higher with disease duration. The indirect cost of supportive care was consistent across groups (€140–€191), meanwhile paid productive loss cost was between €52–€797 and unpaid productivity loss between €25–€415 in A-RSV and P-RSV, respectively. Conclusion: RSV poses a high economic burden in older adults across disease stages, increasing numerically with symptom duration and need for hospitalization, highlighting a need for prevention and continued monitoring.Keywords
Funding Information
- Pfizer
- Pfizer
This publication has 42 references indexed in Scilit:
- RSV Risk Profile in Hospitalized Adults and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010–2022Infectious Diseases and Therapy, 2024
- Healthcare costs related to respiratory syncytial virus in paediatric intensive care units in the Netherlands: a nationwide prospective observational study (the BRICK study)The Lancet Regional Health - Europe, 2024
- Estimated Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain, 2016–2019Infectious Diseases and Therapy, 2024
- Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in EuropeVaccine, 2023
- Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic Review and Modelling StudyInfectious Diseases and Therapy, 2023
- RSV‐associated hospitalization in adults in the USA: A retrospective chart review investigating burden, management strategies, and outcomesHealth Science Reports, 2022
- POSC190 Hospital Utilization for Elderly Patients Diagnosed with Respiratory Syncytial Virus (RSV) Versus Influenza in the USValue in Health, 2022
- Respiratory Syncytial Virus and Associations With Cardiovascular Disease in AdultsJACC, 2018
- Evidence for Validity of a National Physician and Patient-Reported Survey in China and United Kingdom: The Disease Specific ProgrammeValue in Health, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013